Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. More Details
Very undervalued with high growth potential.
Share Price & News
How has Pharming Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PHARM is not significantly more volatile than the rest of Dutch stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PHARM's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: PHARM underperformed the Dutch Biotechs industry which returned 2.8% over the past year.
Return vs Market: PHARM underperformed the Dutch Market which returned 41.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Pharming Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StPharming Group (AMS:PHARM) Shareholders Have Enjoyed A Whopping 400% Share Price Gain
1 month ago | Simply Wall StIs Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?
2 months ago | Simply Wall StPharming Group (AMS:PHARM) Seems To Use Debt Rather Sparingly
Is Pharming Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PHARM (€1.09) is trading below our estimate of fair value (€3.59)
Significantly Below Fair Value: PHARM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PHARM is good value based on its PE Ratio (20.9x) compared to the XE Biotechs industry average (29.9x).
PE vs Market: PHARM is good value based on its PE Ratio (20.9x) compared to the Dutch market (27.4x).
Price to Earnings Growth Ratio
PEG Ratio: PHARM is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: PHARM is good value based on its PB Ratio (4.6x) compared to the XE Biotechs industry average (5.3x).
How is Pharming Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHARM's forecast earnings growth (35% per year) is above the savings rate (0.1%).
Earnings vs Market: PHARM's earnings (35% per year) are forecast to grow faster than the Dutch market (18.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PHARM's revenue (22.5% per year) is forecast to grow faster than the Dutch market (6.8% per year).
High Growth Revenue: PHARM's revenue (22.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PHARM's Return on Equity is forecast to be high in 3 years time
How has Pharming Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHARM has high quality earnings.
Growing Profit Margin: PHARM's current net profit margins (17.8%) are lower than last year (21.4%).
Past Earnings Growth Analysis
Earnings Trend: PHARM has become profitable over the past 5 years, growing earnings by 48.5% per year.
Accelerating Growth: PHARM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PHARM had negative earnings growth (-8.8%) over the past year, making it difficult to compare to the Biotechs industry average (21.8%).
Return on Equity
High ROE: PHARM's Return on Equity (22.1%) is considered high.
How is Pharming Group's financial position?
Financial Position Analysis
Short Term Liabilities: PHARM's short term assets (€214.3M) exceed its short term liabilities (€62.6M).
Long Term Liabilities: PHARM's short term assets (€214.3M) exceed its long term liabilities (€128.8M).
Debt to Equity History and Analysis
Debt Level: PHARM's debt to equity ratio (82.7%) is considered high.
Reducing Debt: PHARM's debt to equity ratio has increased from 62.2% to 82.7% over the past 5 years.
Debt Coverage: PHARM's debt is well covered by operating cash flow (59.9%).
Interest Coverage: PHARM's interest payments on its debt are well covered by EBIT (14.2x coverage).
What is Pharming Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PHARM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PHARM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PHARM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PHARM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PHARM's dividend in 3 years as they are not forecast to pay a notable one for the Dutch market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Simon de Vries (61 yo)
Dr. Sijmen De Vries, also known as Simon, M.D., M.B.A., has been the Chief Executive Officer of Pharming Group NV since November 3, 2008 and also serves as its Executive Director. Dr. De Vries served as Ch...
CEO Compensation Analysis
Compensation vs Market: Simon's total compensation ($USD3.12M) is above average for companies of similar size in the Dutch market ($USD1.19M).
Compensation vs Earnings: Simon's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: PHARM's management team is considered experienced (3 years average tenure).
Experienced Board: PHARM's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PHARM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pharming Group N.V.'s company bio, employee growth, exchange listings and data sources
- Name: Pharming Group N.V.
- Ticker: PHARM
- Exchange: ENXTAM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €695.800m
- Shares outstanding: 641.29m
- Website: https://www.pharming.com
Number of Employees
- Pharming Group N.V.
- Darwinweg 24
- 2333 CR
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company’s lead p...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/10 20:11|
|End of Day Share Price||2021/05/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.